{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=15", "query": { "intervention": "ADV", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 363, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ADV&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T09:45:19.469Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02868073", "title": "Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Norovirus Gastroenteritis" ], "interventions": [ { "name": "VXA-G1.1-NN (high dose) Oral Vaccine Tablet", "type": "BIOLOGICAL" }, { "name": "VXA Placebo Tablets", "type": "OTHER" }, { "name": "VXA-G1.1-NN (low dose) Oral Vaccine Tablet", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 66, "start_date": "2016-07-29", "completion_date": "2017-10-01", "has_results": false, "last_update_posted_date": "2018-05-31", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02868073" }, { "nct_id": "NCT01438112", "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Transitional Cell Carcinoma", "Bladder Cancer", "Carcinoma in Situ", "Carcinoma in Situ Concurrent With Papillary Tumors" ], "interventions": [ { "name": "CG0070 Adenovirus Vector", "type": "BIOLOGICAL" }, { "name": "Control Arm: Quadruple Choice", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-03", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 7, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01438112" }, { "nct_id": "NCT03329248", "title": "QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "lovaza", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-11-06", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329248" }, { "nct_id": "NCT00880789", "title": "Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cytomegalovirus Infection", "Adenovirus Infection" ], "interventions": [ { "name": "CMV/AdV specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "90 Years", "sex": "ALL", "summary": "Up to 90 Years" }, "enrollment_count": 9, "start_date": "2009-05", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-10-15", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00880789" }, { "nct_id": "NCT03583606", "title": "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ebola Disease", "Immunisation" ], "interventions": [ { "name": "ChAd3-EBO-Z", "type": "BIOLOGICAL" }, { "name": "MVA Multi-Filo Ebola Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 61, "start_date": "2018-11-12", "completion_date": "2020-01-14", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03583606" }, { "nct_id": "NCT02218125", "title": "A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MVA Mosaic", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Crucell Holland BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 25, "start_date": "2014-09-23", "completion_date": "2015-11-30", "has_results": false, "last_update_posted_date": "2018-11-27", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02218125" }, { "nct_id": "NCT01945814", "title": "Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EBV", "CMV", "Adenovirus" ], "interventions": [ { "name": "CTL for CMV seropositive donors", "type": "DRUG" }, { "name": "CTL for CMV naïve donors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catherine Bollard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "45 Years", "sex": "ALL", "summary": "4 Weeks to 45 Years" }, "enrollment_count": 27, "start_date": "2014-02", "completion_date": "2018-10-16", "has_results": false, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945814" }, { "nct_id": "NCT00039325", "title": "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "dendritic cell-MART-1 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2002-03", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039325" }, { "nct_id": "NCT00117676", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 382, "start_date": "2005-02", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 17, "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117676" }, { "nct_id": "NCT03754933", "title": "Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Ad/PNP", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GeoVax, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-02-11", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-03-27", "last_synced_at": "2026-10-20T09:45:19.469Z", "location_count": 3, "location_summary": "Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03754933" } ] }